Colorectal cancer spans colon and rectal disease, often engaging WNT/APC, RAS/RAF/MAPK, PI3K, and mismatch-repair (MMR) biology; MSI-H/dMMR links tightly to immunotherapy response. We provide biomarker antibodies (CEA/CA19-9) and readout tools across EGFR, VEGF, and DNA-damage repair for resistance and combination studies.
Focus areas: MSI/MMR & immune milieu, RAS/BRAF stratification & anti-EGFR rules, liver metastasis & angiogenesis, neoadjuvant/perioperative biomarkers
Commonly used for mechanistic studies; follow your lab SOP, compound datasheets, and ethics approvals.
| Compound | Targets / pathways | Experimental notes |
|---|---|---|
| Cetuximab (anti-EGFR mAb) | EGFR (blockade) | Most used in RAS-wildtype contexts; monitor rash and bypass activation. |
| Bevacizumab (anti-VEGF mAb) | VEGF-A | Angiogenesis axis probe; mind BP/wound healing in vivo. |
| Regorafenib | Multi-kinase (VEGFR/KIT/RET/RAF, etc.) | Common in refractory models; dose-window and off-target controls. |
| Trametinib | MEK1/2 | MAPK probe in BRAF-mutant settings; watch RTK feedback. |
| 5-Fluorouracil | TS / DNA synthesis (context-dependent) | Classic backbone; pair with MMR/replication-stress time courses. |
| Oxaliplatin | DNA crosslink / replication stress | ICD-related readouts; often paired with DDR markers (γH2AX). |
| Veliparib | PARP1/2 | Replication stress/BRCAness exploration; matrix DDR toxicities. |